linopristin drug combination flopristin

a mixture of flopristin (RPR132552A) and linopristin (RPR202698)

Also Known As:

flopristin, linopristin drug combination; NXL 103; NXL-103; NXL103; XRP 2868; XRP-2868; XRP2868; flopristin - linopristin; viquidacin

Networked: 4 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Parra-Ruiz, Jorge: 1 article (10/2011)
2.	Rybak, Michael J: 1 article (10/2011)
3.	Vidaillac, Celine: 1 article (10/2011)
4.	Winterfield, Patricia: 1 article (10/2011)
5.	Politano, Amani D: 1 article (02/2010)
6.	Sawyer, Robert G: 1 article (02/2010)
7.	Andes, D: 1 article (01/2006)
8.	Craig, W A: 1 article (01/2006)
9.	Bryskier, Andre: 1 article (01/2005)
10.	Citron, Diane M: 1 article (01/2005)

Related Diseases

1.	Infections 01/01/2006 - "In subsequent studies, we used the neutropenic murine thigh infection model to determine if the magnitude of the AUC/MIC needed for the efficacy of XRP 2868 varied among pathogens (including resistant strains). " 01/01/2006 - "We used the neutropenic murine thigh and lung infection models to characterize the time course of antimicrobial activity of XRP 2868 and determine which pharmacokinetic/pharmacodynamic (PK/PD) parameter and magnitude best correlated with efficacy. " 01/01/2006 - "Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models." 01/01/2005 - "A comparative study of the in vitro activities of XRP 2868, a new oral streptogramin, against 266 anaerobic gram-positive clinical isolates using the agar dilution method showed that the XRP 2868 MICs for 95% (254 of 266) of isolates were < or =0.5 microg/ml. XRP 2868 MICs for only two strains, one being Clostridium clostridioforme (MIC, 16 microg/ml) and the other being Clostridium difficile (MIC, 32 microg/ml), were >2 microg/ml. Depending on its pharmacokinetics and pharmacodynamics, XRP 2868 has potential for use against infections with gram-positive anaerobes and deserves further clinical evaluation."
2.	Pneumonia (Pneumonitis) 02/01/2010 - "NXL-103 has promise to become an important agent in the treatment of community-acquired pneumonia and complex skin and soft tissue infections, pending further development." 02/01/2010 - "NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA." 02/01/2010 - "The first phase II trial conducted to evaluate the efficacy of NXL-103 against community-acquired pneumonia revealed that the compound was comparable with amoxicillin. " 02/01/2010 - "Novexel is developing the novel, orally active, semisynthetic streptogramin NXL-103, which has potential therapeutic application in the treatment of community-acquired pneumonia, community- or hospital-acquired MRSA, vancomycin-resistant enterococcus, and acute bacterial skin and soft tissue infections. "
3.	Soft Tissue Infections 10/01/2011 - "Further in vitro and in vivo experiments are warranted to explore the therapeutic benefit of NXL103 for the treatment of Gram-positive skin and soft-tissue infections." 02/01/2010 - "NXL-103 has promise to become an important agent in the treatment of community-acquired pneumonia and complex skin and soft tissue infections, pending further development." 02/01/2010 - "Novexel is developing the novel, orally active, semisynthetic streptogramin NXL-103, which has potential therapeutic application in the treatment of community-acquired pneumonia, community- or hospital-acquired MRSA, vancomycin-resistant enterococcus, and acute bacterial skin and soft tissue infections. "
4.	Bacterial Infections (Bacterial Infection) 02/01/2010 - "NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA."

Related Drugs and Biologics

1.	Amoxicillin (Wymox)
2.	Streptogramins
3.	Vancomycin
4.	Agar